Financial Performance - The company's revenue for Q3 2022 was ¥206,750,782.03, a decrease of 16.22% compared to the same period last year[8]. - Net profit attributable to shareholders was ¥134,870,084.05, representing a significant increase of 106.75% year-on-year[8]. - The net profit excluding non-recurring gains and losses was ¥44,512,268.54, down 27.10% from the previous year[8]. - Basic earnings per share were ¥0.34, up 112.50% year-on-year[8]. - Total operating revenue for the third quarter was ¥599,258,982.80, a decrease of 7.2% compared to ¥645,735,626.15 in the same period last year[31]. - The net profit for the current period reached CNY 224,157,836.85, an increase of 27% compared to CNY 176,496,035.76 in the previous period[34]. - Operating profit for the current period was CNY 256,234,697.00, up 30% from CNY 197,012,147.36 year-over-year[34]. - Total revenue from operating activities amounted to CNY 664,533,708.69, compared to CNY 601,563,244.71 in the previous period, reflecting a growth of approximately 10.5%[38]. - The basic and diluted earnings per share for the current period were both CNY 0.56, compared to CNY 0.44 in the previous period, representing a 27% increase[37]. - The company reported a total comprehensive income of CNY 224,506,263.64, compared to CNY 176,068,226.97 in the previous period, marking a significant increase[37]. Cash Flow and Liquidity - The company generated a net cash flow from operating activities of ¥145,723,486.86, an increase of 17.24% compared to the same period last year[8]. - Cash flow from operating activities netted CNY 145,723,486.86, an increase from CNY 124,291,686.18 in the previous period[41]. - The cash and cash equivalents at the end of the period were CNY 205,867,355.89, down from CNY 351,613,750.41, indicating a decrease in liquidity[41]. - The net increase in cash and cash equivalents was -29,921,267.86, reflecting a 200.80% decline, attributed to the increase in unexpired financial products[14]. - Investment activities resulted in a net cash outflow of CNY -104,574,928.34, compared to CNY -75,963,355.27 in the previous period, suggesting increased investment efforts[41]. - The company experienced a foreign exchange impact on cash and cash equivalents of CNY 29,793,579.12, contrasting with a negative impact of CNY -4,416,621.27 in the previous period[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,631,372,496.37, an increase of 7.34% from the end of the previous year[8]. - Total assets reached ¥1,631,372,496.37, up from ¥1,519,881,333.25, marking an increase of 7.3%[29]. - Total liabilities were reported at ¥149,736,431.01, a slight decrease from ¥150,250,223.95[29]. - The equity attributable to shareholders was ¥1,481,636,065.36, reflecting an increase of 8.58% year-on-year[8]. - Accounts receivable rose to ¥450,151,772.64, up from ¥428,771,096.72, indicating an increase of 4.5%[24]. - Inventory levels increased to ¥45,668,110.88 from ¥32,270,005.88, representing a significant rise of 41.7%[27]. Investments and Expenses - Financial expenses showed a significant decrease of 1425.13% to -30,268,298.24, primarily due to increased exchange gains[14]. - Investment income increased by 145.17% to 6,835,699.20, driven by higher returns from matured financial products[14]. - Research and development expenses increased to CNY 121,508,871.96, up from CNY 109,167,134.77, indicating a focus on innovation[34]. - Long-term deferred expenses increased by 162.90% to 2,703,377.58 due to increased laboratory construction investments[14]. - Deferred income tax assets decreased by 70.44% to 6,046,162.90 primarily due to a reduction in share-based payment tax assets[14]. - Other non-current assets rose by 98.48% to 12,255,949.00 mainly due to an increase in prepayments for long-term asset purchases[14]. Strategic Developments - The company completed the delivery of materials related to the SDC2 product and the transfer of intellectual property rights during the reporting period[11]. - The company completed the transfer of SDC2 product rights and equity in its subsidiary, indicating strategic market expansion efforts[23]. - The company plans to continue focusing on new product development and technology advancements to drive future growth[23]. - The company repurchased shares, resulting in treasury stock increasing by 137.54% to 77,818,281.09[14]. - The company reported a 5219.51% increase in asset disposal income to 94,550,129.44, primarily from the transfer of SDC2 products and related intellectual property[14]. Reporting and Auditing - The third quarter report of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. is unaudited[44]. - The board of directors released the third quarter report on October 25, 2022[44].

Financial Performance - The company reported a stable growth in revenue, with a year-on-year increase of 15% in the first half of 2022, reaching RMB 500 million[30]. - The company's operating revenue for the reporting period was ¥392,508,200.77, a decrease of 1.62% compared to the previous year[38]. - Net profit attributable to shareholders was ¥89,287,752.80, reflecting a decline of 19.79% year-over-year[38]. - The net profit after deducting non-recurring gains and losses was ¥76,667,754.03, down 23.93% from the same period last year[38]. - The net cash flow from operating activities was ¥70,466,176.75, a decrease of 24.16% compared to the previous year[38]. - Basic earnings per share were ¥0.22, down 21.43% from ¥0.50 in the previous year[38]. - The total assets at the end of the reporting period were ¥1,543,759,338.38, an increase of 1.57% from the end of the previous year[38]. - The net assets attributable to shareholders were ¥1,392,414,802.29, reflecting a growth of 2.04% compared to the previous year[38]. - The company's investment income for the reporting period was ¥4,814,411.25, accounting for 4.55% of total profit, primarily from matured financial products[102]. - The cash and cash equivalents increased by 13.14% to ¥34,578,082.78 from ¥30,560,987.33 year-on-year, reflecting improved liquidity[96]. Market Strategy and Development - The company plans to enhance its international market development efforts, aiming for a 20% increase in overseas sales by the end of 2022[9]. - The company aims to maintain a market share of over 25% in the domestic in vitro diagnostic sector by the end of 2022[15]. - The company is actively expanding its international market presence to ensure stable and healthy growth of its main business[132]. - The overseas revenue increased by 27.34% to ¥57,169,926.10, compared to ¥44,897,100.51 in the same period last year, indicating successful market expansion efforts[100]. - The company has established a direct sales network covering over 500 top hospitals in China, supported by a sales team of over 400 people[88]. Research and Development - The R&D investment for new product development was RMB 50 million, representing 10% of total revenue, to ensure alignment with market demands[10]. - The company invested CNY 77.84 million in R&D during the reporting period, representing a year-on-year increase of 14.19% and accounting for 19.83% of its operating revenue[82]. - The company has developed and approved 24 types of single-gene and multi-gene tumor diagnostic products, maintaining a leading position in the industry[46]. - The company has developed key technology platforms including PCR, NGS, IHC, and FISH, with proprietary patents driving long-term growth[76]. - The company’s R&D team comprises 451 professionals with expertise in various fields, ensuring a flexible and efficient project management approach[83]. Product and Service Offerings - The company offers a wide range of cancer detection services, including lung, colorectal, breast, and ovarian cancer, with service cycles typically ranging from 1 to 10 days[61]. - The testing reagent business generated revenue of ¥29,508.35 million during the reporting period[48]. - The company's testing services generated revenue of 73.6957 million yuan during the reporting period[61]. - The company has established partnerships with leading medical institutions to promote personalized cancer treatment systems, contributing to its innovation and market expansion[84]. - The company is focusing on expanding its product offerings in genetic testing, with several new products under development and registration[56]. Compliance and Risk Management - The company is actively monitoring policy changes in the healthcare sector to mitigate potential risks associated with regulatory adjustments[7]. - The company has implemented a comprehensive cost control strategy, which is expected to improve operational efficiency by 15% in the next fiscal year[14]. - The company is committed to compliance and innovation, aligning with regulatory requirements and industry trends to enhance the clinical value of its products[74]. - The company has maintained a strong governance structure, ensuring compliance with laws and regulations, and protecting investor interests[154]. - The company has not faced any significant administrative penalties or environmental violations during the reporting period[151]. Corporate Social Responsibility - The company has actively participated in public welfare projects, providing free low-dose spiral CT lung cancer screenings for over 3,000 high-risk patients[157]. - The company has implemented measures to reduce carbon emissions, aligning with national goals of "carbon peak and carbon neutrality"[152]. - The company has committed to sustainable development and environmental protection throughout its operational processes[157]. - The company has actively contributed to the local community by supporting COVID-19 testing efforts and donating to the Red Cross[157]. Shareholder and Equity Management - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year, focusing on reinvestment for growth[16]. - The company has implemented a stock incentive plan, with 111 individuals eligible for the release of restricted shares as of May 16, 2022, and 83 individuals for the second release as of May 10, 2022[147]. - The company has completed the repurchase and cancellation of 215,625 restricted shares under its stock incentive plan as of May 20, 2022[148]. - As of June 30, 2022, the company repurchased 694,800 shares, accounting for 0.17% of the total share capital, with a total payment of approximately RMB 32.12 million[200]. - The company implemented a profit distribution plan, distributing RMB 2.30 per 10 shares and increasing capital by 8 shares for every 10 shares held[197].

证券代码：300685 证券简称：艾德生物 公告编号：2022-034 厦门艾德生物医药科技股份有限公司 关于举行 2021 年度网上业绩说明会暨参加 厦门辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"）已于2022年4 月12日在巨潮资讯网（http://www.cninfo.com.cn/）披露了公司2021年年 度报告及其摘要，为便于广大投资者进一步了解公司2021年度经营情况，公司 将召开2021年度业绩说明会暨参加由厦门证监局、厦门上市公司协会与深圳市 全景网络有限公司联合举办的"2021年年报业绩说明会暨投资者网上集体接待 日"活动。具体如下： 一、召开时间 2022年5月10日（星期二）14:30－16:00 二、召开方式 本次活动将采用网络远程的方式举行，届时投资者可登录全景网投资者关系 互动平台（http://ir.p5w.net）参与互动交流。公司相关人员将与投资者就公 司治理、经营状况、发展战略、投资者保护等问题进行沟通。 三、出席人员 出席本 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥206,049,845.51, representing an increase of 18.60% compared to ¥173,734,244.08 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2022 was ¥53,614,836.90, up 23.46% from ¥43,427,819.49 in the previous year[6]. - The net profit after deducting non-recurring gains and losses was ¥49,077,254.65, reflecting a 25.82% increase from ¥39,006,740.62 year-on-year[6]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.24, a 20.00% increase from ¥0.20 in the previous year[6]. - Total operating revenue for the first quarter reached ¥206,049,845.51, an increase of 18.5% compared to ¥173,734,244.08 in the previous year[34]. - Net profit for the period was ¥53,336,627.60, representing a 22.8% increase from ¥43,427,812.07 in the same quarter last year[36]. - Total comprehensive income for the period was CNY 53,336,627.60, compared to CNY 43,427,812.07 in the previous period, representing a growth of approximately 23.5%[40]. - Basic and diluted earnings per share increased to CNY 0.24 from CNY 0.20, reflecting a 20% increase[40]. Cash Flow - The net cash flow from operating activities decreased by 55.14% to ¥27,961,142.84, down from ¥62,324,682.53 in the same period last year[6]. - Cash inflow from operating activities was CNY 198,916,694.38, slightly down from CNY 200,900,983.53, indicating a decrease of about 1%[42]. - The company's total cash inflow from operating activities was CNY 198,916,694.38, while cash outflow was CNY 170,955,551.54, resulting in a net cash flow of CNY 27,961,142.84[42]. - Cash outflow for investing activities totaled CNY 107,925,200.78, down from CNY 341,804,650.87, a reduction of about 68%[47]. - Net cash flow from investing activities was negative at CNY -140,286.55, compared to CNY -45,331,843.78 in the previous period[47]. - Cash flow from financing activities resulted in a net outflow of CNY -17,034,520.27, compared to CNY -356,217.29 previously[47]. - The ending cash and cash equivalents balance was CNY 245,046,650.76, down from CNY 376,231,190.87, a decrease of approximately 34.8%[47]. - The company reported a decrease in cash received from investment recovery to CNY 105,000,000.00 from CNY 294,000,000.00, a decline of about 64.2%[46]. Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,535,133,046.49, a 1.00% increase from ¥1,519,881,333.25 at the end of the previous year[6]. - Total liabilities decreased to ¥124,170,461.08 from ¥150,250,223.95, a reduction of 17.4%[30]. - The company's equity attributable to shareholders rose to ¥1,406,060,373.19, up from ¥1,364,580,687.78, indicating a growth of 3.1%[33]. - The cash and cash equivalents increased to ¥1,212,452,945.83 from ¥1,196,020,727.99, reflecting a growth of 1.3%[33]. - The company reported a decrease in accounts payable from ¥24,021,136.22 to ¥16,276,754.19, a decline of 32.2%[30]. - The company’s deferred income tax assets increased to ¥21,056,557.57 from ¥20,457,300.33, showing a growth of 2.9%[33]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,119[14]. - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 21.97% of shares, totaling 48,723,120 shares[14]. - The total number of common shares held by the top ten shareholders accounts for a significant portion of the company's equity[14]. - The company has implemented a stock incentive plan, with a total of 2,123,700 restricted shares at the beginning of the period[21]. - The company has not identified any related party relationships among the top shareholders, except for a mother-daughter relationship between two of the shareholders[17]. Research and Development - Research and development expenses were ¥38,760,861.03, which is a 18.5% increase compared to ¥32,700,720.91 in the previous year[34]. - In January 2022, the PCR-11 gene product was included in Japan's medical insurance[22]. - In March 2022, the PD-L1 antibody reagent received approval from the National Medical Products Administration[22]. Expenses - Sales expenses for Q1 2022 were ¥61,722,822.00, an increase of 42.82% compared to ¥43,217,128.57 in the same period last year[10]. - Total operating costs amounted to ¥151,509,513.28, up from ¥125,941,512.78, reflecting a year-over-year increase of 20.4%[34]. - Investment income for Q1 2022 was ¥1,774,558.80, a significant increase of 210.40% from ¥571,701.45 in the previous year[13]. - The net cash flow from investing activities improved by 99.69%, with a net outflow of ¥140,286.55 compared to a much larger outflow of ¥45,331,843.78 in the same period last year[13].

Financial Performance - The company's operating revenue for 2021 was ¥917,033,391.28, representing a 25.90% increase compared to ¥728,390,555.97 in 2020[36]. - The net profit attributable to shareholders for 2021 was ¥239,573,622.91, a 32.86% increase from ¥180,326,353.21 in 2020[36]. - The net profit after deducting non-recurring gains and losses was ¥215,656,757.15, which is a 46.54% increase compared to ¥147,169,566.28 in 2020[36]. - The company's total assets at the end of 2021 were ¥1,519,881,333.25, up 17.56% from ¥1,292,897,713.11 at the end of 2020[36]. - The basic earnings per share for 2021 was ¥1.09, reflecting a 32.93% increase from ¥0.82 in 2020[36]. - The weighted average return on equity for 2021 was 19.19%, an increase from 17.84% in 2020[36]. - The net cash flow from operating activities for 2021 was ¥168,161,324.14, a decrease of 23.80% from ¥220,694,485.33 in 2020[36]. - The company reported a total of ¥173,734,244.08 in revenue for Q1 2021, with a net profit of ¥43,427,819.49[41]. - The company received government subsidies amounting to ¥19,459,460.20 in 2021, compared to ¥33,017,759.98 in 2020[44]. - The total net assets attributable to shareholders at the end of 2021 were ¥1,364,580,687.78, a 20.92% increase from ¥1,128,491,766.09 at the end of 2020[36]. Market Strategy and Expansion - The company aims to enhance its domestic market share and actively expand into international markets to ensure stable revenue growth[16]. - The company recognizes the increasing competition in the in vitro diagnostic market and is adapting its sales strategy to combine direct sales with distribution channels[17]. - The company intends to protect its intellectual property and core technologies while enhancing customer loyalty to maintain its competitive edge[17]. - The company is focused on improving operational management and utilizing information technology to optimize procurement, production, and sales processes[11]. - The company aims to expand its international strategy and strengthen overseas product registration and market access[79]. Research and Development - The company plans to strengthen its research and development capabilities to meet current and future market demands for in vitro diagnostic products[12]. - R&D investment for 2021 was 156 million yuan, representing a year-on-year growth of 35.63% and accounting for 17.02% of total revenue[87]. - The company has established a strong R&D team of 451 personnel, covering various fields such as molecular biology and clinical medicine[88]. - The company has developed and approved 24 single-gene and multi-gene diagnostic products, making it a leader in the industry with the most comprehensive product range[56]. - The company has received new medical device registrations for products including the SDC2 gene methylation testing kit, effective from January 5, 2021, to January 4, 2026[64]. Product and Service Offerings - The company operates in the rapidly growing molecular diagnostics sector, focusing on precision oncology, driven by increasing cancer incidence and aging population[51]. - The company's testing services business achieved revenue of 154.91 million yuan, representing a year-on-year growth of 33.43%[69]. - The company offers a wide range of cancer detection services, including lung cancer, colorectal cancer, and breast cancer, with service cycles typically ranging from 1 to 10 days[69]. - The company’s products have been approved in over 60 countries and regions, establishing partnerships with major pharmaceutical companies like AstraZeneca and Pfizer[56]. - The company’s testing reagent sales accounted for 76.23% of total revenue, amounting to approximately ¥699 million, with a year-on-year growth of 23.83%[114]. Risk Management - The company is aware of the risks associated with industry policy changes and is committed to monitoring market dynamics to mitigate potential impacts[9]. - The company has maintained a high gross margin but acknowledges potential risks from increased competition and rising costs, and plans to implement cost control measures[189]. - The company recognizes risks from industry policy changes and plans to enhance market analysis and management to mitigate these risks[185]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective oversight and operational coordination[196]. - The company has a board of directors consisting of 9 members, including 3 independent directors, complying with legal and regulatory requirements[199]. - The supervisory board consists of 3 members, including 1 employee representative, meeting legal and regulatory standards[200]. - The company maintains independence from its controlling shareholder in business, personnel, assets, institutions, and finance[198]. Investment and Financial Management - The total amount raised from the initial public offering (IPO) was RMB 277.2 million, with a net amount of RMB 247.23 million after deducting issuance costs of RMB 29.97 million[155]. - The company has committed to invest a total of RMB 83.89 million in the molecular diagnostic reagents and second-generation sequencer industrialization project, with 100% investment progress achieved by June 30, 2020[156]. - The company has achieved 100% investment progress for the project aimed at supplementing working capital and repaying bank loans, totaling RMB 5 million[159]. - The company has maintained strict control over expenditures, resulting in savings on project costs and ensuring the completion of investment projects[168]. - The company has generated investment income from cash management of idle funds, with a balance of RMB 11,697.64 in the special fund account after deducting fees[168].

Financial Performance - The company's revenue for Q3 2021 was ¥246,782,770.58, representing a 22.78% increase year-over-year, and total revenue for the year-to-date reached ¥645,735,626.15, up 33.41% compared to the same period last year[6] - Net profit attributable to shareholders for Q3 2021 was ¥65,233,520.52, a 43.92% increase year-over-year, while the year-to-date net profit reached ¥176,555,722.68, up 39.98%[6] - The basic earnings per share for Q3 2021 was ¥0.29, reflecting a 38.10% increase compared to the same period last year, with diluted earnings per share also at ¥0.29[6] - Total operating revenue for the third quarter reached ¥645,735,626.15, an increase of 33.4% compared to ¥484,020,471.55 in the same period last year[36] - Net profit for the period was ¥176,496,035.76, representing a 40% increase from ¥126,130,439.48 in the previous year[36] - Total comprehensive income attributable to the parent company was approximately CNY 176.07 million, an increase from CNY 125.94 million in the previous period, representing a growth of 40%[40] - Basic and diluted earnings per share increased to CNY 0.79 from CNY 0.57, reflecting a growth of 38.6%[40] Assets and Liabilities - The company's total assets as of the end of Q3 2021 were ¥1,427,766,629.51, a 10.43% increase from the end of the previous year[6] - Total assets increased to ¥1,427,766,629.51, up from ¥1,292,897,713.11, marking a growth of 10.4%[34] - Total liabilities decreased to ¥123,931,289.91 from ¥164,405,947.02, a reduction of 24.5%[34] - The total liabilities amounted to ¥164,405,947.02, with current liabilities at ¥149,730,859.80[54] - The company reported a non-current liability of ¥14,675,087.22, which includes deferred income of ¥14,621,720.82[54] - The total equity attributable to shareholders of the parent company is ¥1,128,491,766.09[57] Cash Flow - The cash flow from operating activities for the year-to-date was ¥124,291,686.18, showing a decrease of 16.75% compared to the same period last year[6] - Cash inflow from operating activities totaled CNY 601.56 million, up from CNY 501.78 million, indicating a year-over-year increase of 19.9%[44] - Cash outflow from operating activities was CNY 477.27 million, compared to CNY 352.48 million in the previous period, resulting in a net cash flow from operating activities of CNY 124.29 million, down from CNY 149.30 million[44] - Investment activities generated a net cash outflow of CNY 75.96 million, an improvement from a net outflow of CNY 213.65 million in the previous period[44] - The company received CNY 5.25 million from financing activities, a decrease from CNY 72.80 million in the previous period[44] Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,306, with the top 10 shareholders holding a combined 57.27%[16] - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 21.97% of shares, totaling 48,723,120 shares[16] - The number of shares held by the top 10 unrestricted shareholders includes Forward Investment (Hong Kong) Limited with 48,723,120 shares[16] - The company has a total of 2,123,700 restricted shares, all subject to unlocking according to the 2019 stock incentive plan[21] - The total number of restricted shares held by core management and technical personnel is 1,105,200, subject to unlocking regulations[21] - The company has not identified any related party relationships among the top shareholders, except for familial ties between certain partners[20] Operational Costs and Expenses - The company experienced a 70.09% increase in operating costs, totaling ¥103,791,219.27, mainly due to higher costs associated with multi-gene joint reagent products and increased testing service costs[12] - Total operating costs amounted to ¥457,191,133.58, up from ¥360,802,462.50, reflecting a year-over-year increase of 26.7%[36] - Research and development expenses were ¥109,167,134.77, which is a 26.2% increase compared to ¥86,512,568.40 from the same period last year[36] - The company's financial expenses increased by 112.83% to ¥2,284,183.71, primarily due to increased exchange losses[12] - The company reported a significant reduction in other payables, decreasing from ¥78,402,545.82 to ¥33,936,655.44, indicating improved financial management[31] Market Strategy - The company plans to expand its market presence and invest in new product development to drive future growth[36] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[46] Other Financial Information - The company's cash and cash equivalents as of September 30, 2021, amount to ¥346,613,750.41, a decrease from ¥361,560,881.46 at the end of 2020[25] - Accounts receivable increased to ¥403,918,807.11 from ¥316,510,008.54 year-over-year[25] - Inventory has risen to ¥35,688,034.43, compared to ¥21,433,011.25 at the end of 2020[25] - The company reported a total asset value of CNY 1.29 billion, slightly down from CNY 1.29 billion in the previous period[51] - The total liabilities amounted to CNY 23.53 million, with accounts payable at CNY 14.04 million and contract liabilities at CNY 9.48 million[51] - The company has implemented new leasing standards starting from 2021, affecting prior comparative data[57] - The report indicates a capital reserve of ¥441,942,648.04 and a share capital of ¥221,808,000.00[54] - The company has a total of ¥78,402,545.82 in other payables, which includes employee compensation of ¥35,325,504.89[54] - The company reported a total of ¥2,050,135.96 in lease liabilities[54]

Business Performance - The company reported a stable and healthy development of its main business, focusing on international market expansion to mitigate operational risks from policy changes[8]. - The company achieved operating revenue of CNY 398,952,855.57, representing a year-on-year increase of 40.96%[28]. - The net profit attributable to shareholders was CNY 111,322,202.16, up 37.77% compared to the same period last year[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 100,787,048.75, reflecting a growth of 55.98% year-on-year[28]. - The basic earnings per share increased to CNY 0.50, a rise of 38.89% from CNY 0.36 in the previous year[28]. - The total assets at the end of the reporting period were CNY 1,358,178,931.59, marking a 5.05% increase from the end of the previous year[28]. - The net assets attributable to shareholders reached CNY 1,230,175,624.39, which is a 9.01% increase compared to the previous year[28]. Market Opportunities - The domestic in vitro diagnostic market is expected to grow rapidly due to economic development and healthcare reforms, presenting significant opportunities for the company[12]. - The molecular diagnostics market is expected to expand into broader applications, including genetic risk assessment and disease monitoring, driven by advancements in precision medicine technology[54]. - The demand for tumor precision medical diagnostic products is projected to increase annually due to the rising number of cancer patients and extended survival rates[58]. Product Development and Innovation - The company emphasizes the importance of continuous product innovation to maintain competitive advantages in the rapidly evolving in vitro diagnostic industry[9]. - The company's main business focuses on molecular diagnostics for cancer precision medicine, with a comprehensive product line and strong R&D capabilities[36]. - The company has obtained 45 patent authorizations and has developed 23 single-gene and multi-gene molecular diagnostic products approved by the NMPA[36]. - The company has developed proprietary technologies such as ADx-ARMS®, Super-ARMS®, and ddCapture®[75]. - The company has established independent third-party medical testing institutions, certified by the health authorities, to provide professional molecular testing services[47]. Financial Management - The company will not distribute cash dividends or issue bonus shares, focusing on reinvestment for growth[13]. - The company has received government subsidies contributing to 6.36% of total profit, amounting to ¥7,956,835.23[86]. - The total amount of raised funds is RMB 247.23 million after deducting issuance costs of RMB 29.97 million[98]. - The cumulative amount of raised funds invested is RMB 256.64 million, with no new investments during the reporting period[96]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[108]. Research and Development - The company reported a research and development investment of 68.16 million yuan, representing a year-on-year increase of 28.96% and accounting for 17.09% of total revenue[73]. - The company has established a strong R&D team of 338 personnel, including over 20 PhDs and nearly 200 master's degree holders[70]. - The company has been focusing on expanding its product offerings and enhancing its research and development capabilities[186]. Operational Efficiency - The company has implemented a strict management philosophy focused on cost control, quality assurance, and efficiency improvement, contributing to steady growth in its main business[60]. - The company employs a centralized procurement management system to ensure the quality and supply of raw materials for production[50]. - The production process for molecular diagnostic reagents includes automated steps, ensuring efficiency and compliance with regulatory standards[52]. International Expansion - The company has successfully entered markets in over 60 countries and regions, establishing partnerships with major pharmaceutical companies[36]. - The company has established an international business team covering over 60 countries and regions, actively seeking partnerships with local distributors and multinational pharmaceutical companies[53]. - The company is actively expanding its international market presence, with subsidiaries in Singapore, Hong Kong, and Canada[77]. Corporate Governance - The company has established a governance structure that ensures clear responsibilities and effective checks and balances, enhancing corporate governance levels[130]. - The company has not engaged in any major related party transactions during the reporting period, ensuring financial integrity[141]. - The company has maintained a commitment to improving information disclosure quality, ensuring equal access to information for all shareholders[130]. Shareholder Management - The company completed the first lock-up period release of the 2019 restricted stock incentive plan, with the listing date on May 12, 2021[160]. - A total of 85,500 restricted shares were repurchased and canceled during the reporting period[161]. - The total number of shares decreased from 221,808,000 to 221,722,500, reflecting a reduction of 85,500 shares[161]. - The company’s stock incentive plan includes provisions for unlocking shares based on performance and tenure[164]. Legal and Compliance - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[139]. - The company has not provided any guarantees that violate regulations during the reporting period, maintaining compliance[135]. - The half-year financial report has not been audited, which may affect the perception of financial transparency[136].

Financial Performance - The company's revenue for Q1 2021 was ¥173,734,244.08, representing a 91.65% increase compared to ¥90,653,754.15 in the same period last year[8] - Net profit attributable to shareholders was ¥43,427,819.49, up 67.59% from ¥25,912,928.63 year-on-year[8] - The net profit excluding non-recurring gains and losses reached ¥39,006,740.62, a significant increase of 183.25% from ¥13,771,012.38 in the previous year[8] - The net cash flow from operating activities was ¥62,324,682.53, reflecting a 30.25% increase compared to ¥47,850,460.42 in the same period last year[8] - Basic and diluted earnings per share were both ¥0.2, an increase of 11.11% from ¥0.18[8] - The company reported a significant increase in cash received from investment activities, totaling 296,472,807.09, compared to 30,293,194.52 in the previous period[105] - The total comprehensive income for the current period is 41,631,458.54, compared to 26,950,418.12 in the previous period, indicating a growth of about 54.4%[100] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,346,320,457.05, a 4.13% increase from ¥1,292,897,713.11 at the end of the previous year[8] - The company's total liabilities were CNY 166,291,899.72, slightly up from CNY 164,405,947.02, marking an increase of approximately 1.1%[72] - The equity attributable to shareholders of the parent company increased to CNY 1,180,028,564.75 from CNY 1,128,491,766.09, representing a growth of about 4.6%[75] - The company's total current assets reached CNY 1,029,349,983.25, up from CNY 1,008,764,262.12, indicating an increase of about 2.9%[66] Shareholder Information - The total number of shareholders at the end of the reporting period was 19,695[12] - The largest shareholder is Forward Investment (Hong Kong) Limited, holding 21.97% with 48,723,120 shares[15] - The second largest shareholder is Hong Kong Central Clearing Limited, holding 6.88% with 15,260,868 shares[15] - The third largest shareholder is Xiamen Haicang Yixiang Investment Partnership (Limited Partnership), holding 6.69% with 14,834,700 shares[15] - The company has a total of 4,040,400 restricted shares, with 118,125 shares released during the reporting period[22] Research and Development - Research and development expenses increased by 54.36% to ¥32,700,720.91, up from ¥21,184,841.62, attributed to higher costs for R&D materials and personnel[26] - The company is committed to continuous product innovation and development to meet current and future market demands[38] - The company has a strong R&D capability and ongoing technical accumulation to support new product launches[38] Market Strategy - The company plans to continue expanding its market presence and product clinical applications, focusing on precision medicine and companion diagnostics[30] - The company aims to improve domestic market share and actively expand overseas markets to ensure stable revenue growth[39] - The company is focusing on enhancing product quality and customer loyalty to maintain competitive advantages amid increasing market competition[40] Investment and Financial Management - The total amount of raised funds is RMB 123.17 million, with 49.82% of the total raised funds having been redirected[46] - The company has invested RMB 534.44 million in the molecular diagnostic reagents and second-generation sequencing industrialization project, achieving 100% of the planned investment[46] - The company is closely monitoring market trends and industry changes to maximize the investment efficiency of raised funds[49] - The company has saved a portion of the raised funds by strictly controlling expenditures during the implementation of investment projects, leading to reduced actual spending[54] Operational Efficiency - The company emphasizes strict cost control and efficiency improvement to safeguard and enhance profitability[39] - The company experienced a 160.97% increase in operating costs, which reached ¥30,306,899.36, up from ¥11,613,132.86, in line with revenue growth[26] - The company is actively monitoring industry policy changes and enhancing its management practices to mitigate potential risks associated with regulatory adjustments[33] Miscellaneous - The company established a joint venture, Xiamen Xavi Health Technology Co., Ltd., with a registered capital of RMB 10 million, holding a 60% stake[41] - The company has not reported any violations regarding external guarantees during the reporting period[60] - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[61] - The first quarter report was not audited, indicating that the financial results are preliminary[115]

Research and Development - The company reported a significant focus on research and development to meet market demands, ensuring a robust pipeline of in vitro diagnostic products[9] - The company is focused on attracting top talent through improved compensation and incentive mechanisms to support ongoing innovation[9] - R&D investment reached 115.11 million yuan, a year-on-year increase of 22.77%, accounting for 15.80% of operating revenue[79] - The company’s R&D team consists of 274 members, including over 20 PhDs and more than 100 master's degree holders[75] - The company plans to maintain its R&D investment levels in 2021, aiming to enhance its research capabilities and expedite key project advancements[191] - The company is committed to continuous innovation in technology and product development to provide comprehensive solutions for tumor precision medicine[191] Financial Performance - The company's operating revenue for 2020 was ¥728,390,555.97, representing a 25.94% increase compared to ¥578,355,544.11 in 2019[29] - The net profit attributable to shareholders for 2020 was ¥180,326,353.21, which is a 33.11% increase from ¥135,474,211.31 in 2019[29] - The basic earnings per share for 2020 was ¥0.82, down 12.77% from ¥0.94 in 2019[29] - The total assets at the end of 2020 were ¥1,292,897,713.11, a 23.51% increase from ¥1,046,774,057.97 at the end of 2019[29] - The net assets attributable to shareholders at the end of 2020 were ¥1,128,491,766.09, reflecting a 25.10% increase from ¥902,105,138.07 at the end of 2019[29] - The cash flow from operating activities for 2020 was ¥220,694,485.33, which is a 45.65% increase compared to ¥151,524,817.84 in 2019[29] - The company achieved a revenue of 728.39 million yuan in 2020, representing a year-on-year growth of 25.94%[92] - The net profit attributable to shareholders was 180.33 million yuan, an increase of 33.11% compared to the previous year[92] Market Expansion - The domestic market share is being actively increased while expanding into international markets to achieve stable revenue growth[12] - The company has established a strong presence in over 60 countries and regions, partnering with major pharmaceutical companies like AstraZeneca, Pfizer, and Merck for companion diagnostics[44] - The company aims to continue expanding its product offerings and market reach in the field of precision oncology diagnostics[44] - The company has expanded its international presence, with products now available in over 60 countries and regions[97] - The company will enhance its international market development efforts, including new product certifications and establishing deeper collaborations with tumor experts and pharmaceutical companies[196] Product Development and Innovation - The company has developed and launched innovative products such as ADx-ARMS®, Super-ARMS®, and ddCapture®, which cater to various tumor types and sample types for comprehensive management of cancer patients[45] - The Super-ARMS EGFR kit was the first product in China approved for marketing under the companion diagnostic reagent standard by the NMPA[44] - The company successfully developed and approved 23 molecular diagnostic products, including unique products in the domestic market[88] - The company launched several new products, including SDC2, PD-L1, and Classic panel, in response to clinical needs and market demands[92] - The company is advancing the development of PD-L1 (IHC platform) products, which are in the final stages of registration approval[109] Regulatory Environment - The company emphasizes the importance of monitoring policy changes in the healthcare sector, which could impact operations[7] - The regulatory environment is increasingly supportive of companion diagnostics, with multiple policies issued to promote and standardize the industry[65] Customer and Market Strategy - The company is actively exploring a combination of direct sales and distribution channels to enhance market penetration and product recognition[13] - The sales strategy combines direct sales and distribution, with a domestic sales team of over 300 people and an international business team covering over 60 countries[61] - The company aims to strengthen its domestic marketing network, focusing on direct sales while expanding its coverage and penetration in key cancer areas[195] Cost Management - The company has implemented strict cost control measures to safeguard and improve profitability amidst rising operational costs[9] - The main business costs for testing reagents amounted to ¥32,094,739.46, accounting for 33.80% of total operating costs, a decrease from 42.91% in 2019[133] - The main business costs for testing services reached ¥35,251,647.58, representing 37.13% of total operating costs, an increase of 81.94% compared to ¥19,375,777.47 in 2019[133] Talent and Human Resources - The company has established a talent strategy focusing on attracting and nurturing high-quality professionals, granting 790,500 restricted stock units to 102 core management and technical personnel[113] - The company will prioritize human resource development, particularly in R&D and sales positions, to strengthen its competitive advantage[199] Investment and Financial Management - The total amount of raised funds was ¥247,230,000.00, with ¥10,947.19 million utilized during the reporting period, representing 49.82% of the total raised[160] - The company generated interest income from idle funds, contributing to the surplus of raised funds[175] - The company has decided to terminate the molecular diagnostic reagents and second-generation sequencing instrument industrialization project to maximize investment efficiency and reduce risks, reallocating the remaining funds for working capital[168]

Financial Performance - Net profit attributable to shareholders was ¥45,325,881.41, representing a growth of 47.67% year-on-year[8]. - Operating revenue for the period was ¥200,992,255.39, reflecting a year-on-year increase of 37.15%[8]. - The total comprehensive income for the current period was ¥45,226,283.10, compared to ¥30,809,796.11 in the previous period, representing an increase of approximately 47%[65]. - Total operating revenue for the current period reached ¥484,020,471.55, an increase of 17.4% compared to ¥412,461,054.84 in the previous period[73]. - Net profit for the current period was ¥117,697,122.80, up from ¥95,878,043.64 in the previous period, reflecting a growth of approximately 22.8%[87]. - The total profit for the current period was ¥144,044,330.44, compared to ¥128,698,575.48, an increase of 11.8%[76]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,227,079,171.46, an increase of 17.22% compared to the end of the previous year[8]. - Current liabilities totaled ¥162,331,932.55, an increase from ¥140,567,109.42, reflecting a rise of about 15.5%[45]. - Total liabilities reached ¥169,522,469.08, up from ¥144,668,919.90, marking an increase of around 17.1%[45]. - Owner's equity totaled ¥1,057,556,702.38, compared to ¥902,105,138.07, reflecting an increase of approximately 17.3%[48]. - The company's total liabilities were ¥140,567,109.42, consistent with the previous reporting period[107]. Cash Flow - The net cash flow from operating activities was ¥59,989,170.46, up by 13.89% compared to the same period last year[8]. - Cash received from operating activities rose by 96.46% to ¥44,680,816.13, mainly due to increased government subsidies[29]. - Cash flow from operating activities was ¥149,300,432.53, compared to ¥134,307,958.21 in the previous period, showing an increase of approximately 11.2%[93]. - Net cash flow from operating activities was ¥122,530,438.39, up from ¥110,768,247.55, reflecting a growth of 10.4%[97]. - The company reported a net cash outflow from investment activities of ¥213,649,923.74, worsening from a net outflow of ¥108,310,815.37 in the previous period[93]. Shareholder Information - The total number of shareholders at the end of the reporting period was 16,809[14]. - The largest shareholder, Foresee Investment (Hong Kong) Co., Ltd., held 22.95% of the shares[14]. - The top 10 shareholders hold a total of 50,942,520 shares, representing a significant portion of the company's equity[20]. - The company has no preferred shareholders as indicated in the report[21]. - The company has not reported any financing or margin trading activities among its top shareholders during the reporting period[20]. Research and Development - Research and development expenses grew by 32.31% to ¥86,512,568.40, driven by increased costs for R&D materials and personnel[27]. - Research and development expenses for the current period were ¥86,512,568.40, up from ¥65,386,986.38, indicating a growth of 32.3%[76]. - Research and development expenses increased to ¥72,864,944.96 from ¥58,676,222.43, marking a rise of about 24.1%[84]. Government Subsidies - The company recorded government subsidies amounting to ¥23,784,026.41 during the reporting period[9]. - The company reported a 63.66% increase in other income, totaling ¥23,784,026.41, primarily from government subsidies[27]. Inventory and Receivables - Accounts receivable rose by 129.76% to ¥2,511,507.73, attributed to an increase in bank acceptance bill settlements for sales[27]. - Inventory increased by 112.05% to ¥36,392,133.08, mainly due to higher procurement of raw materials[27]. - Accounts receivable increased to ¥270,189,804.29 from ¥229,612,373.08, showing a growth of approximately 17.7%[49]. Financial Position - The company has a total of 123 core management and technical personnel eligible for stock incentives after accounting for departures[24]. - The company has a capital reserve of CNY 437,032,877.21, which supports future growth initiatives[120]. - The company has an unallocated profit of CNY 328,228,215.75, contributing to retained earnings[120].